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The aim of our study was to investigate the efficacy of selective serotonin reuptake inhibitor in patients with chronic back pain. Methods: In this trial we used SSRI fluoxetin on 60 patients (42 women and 18 men) with chronic back pain in age from 45 till 60. Mostly the main cause of dorsalgia was chronic osteoporosis (80%). Patient received a drug once a day in a 20 mg dose for 6 weeks. Before start of trial all the patients discontinued using of NSAIDs. To evaluate the pain we used visual analog scale of pain. Results: Using a SSRI fluoxetin has shown a very good results. 29 patients (48,3%) of patient have shown significant reducing of pain during treatment (decreasing of VAS from average 4.9 till 1.5), 28 patients (46,6%) have shown slightly less reducing of pain (decreasing of VAS from average 4.5 till 2.6), 3 patients (5%) quitted the trial in first week due to adverse effects (nausea, insomnia, sexual disorders).
Conclusion:
In the end of trial all the patients continued to use the drug on their own. We can recommend to use SSRIs as a part of complex therapy of low back pain, due to its safety and high efficacy
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Effect of Antidepressant Treatment on BDNF concentrations in Patients with Somatization Disorders
Jong-Chul Yang, Nam-In Kang, Jong-Il Park, Yong-Ku Kim
Abstract Objective: Brain-derived neurotrophic factor (BDNF) is known to be involved in the plasticity of neurons and pathophysiology of several psychiatric illnesses. The purpose of this study was to determine whether there is an abnormality of plasma BDNF concentrations in patients with somatization disorder, and the alteration after antidepressant treatment.
Methods:
The 27 patients with somatization disorder (mean age: 46.33 ± 9.73 years, 12 males, 15 females) who fulfilled the DSM-IV criteria for somatization disorder and 27 healthy controls (mean age: 46.81 ± 6.81 years, 12 males, 15 females) were enrolled in the study. The clinical assessment of the somatization disorder was measured by Korean version of Wahler physical symptom inventory, Beck Depression Inventory, Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale. BDNF was assayed using the DuoSet ELISA Development System (R&D Systems. DY248). The difference in the plasma BDNF levels between patients and healthy controls was analyzed using non-parametric MannWhitney test by the SPSS 15.0 (p<0.05). Moreover, we assessed the alteration of plasma BDNF concentrations after treatment using Wilcoxon Signed Ranks test. 22 among 27 patients with somatization disorder took the selective serotonin reuptake inhibitors for 9 to 16 weeks. And the correlations between the BDNF level and the clinical assessment scale scores were examined using Spearman correlation coefficient. Results: The mean plasma BDNF levels of 27 patients with somatization disorder were significantly lower compared with those of controls (83.61 ± 89.97 pg/ml vs. 771.36 ± 562.14 pg/ ml, Z=-5.735, p<0.001). In 22 patients after the antidepressant treatment, the plasma BDNF concentrations were significantly increased (118.13 ± 91.45 pg/ml vs. 72.92 ± 88.21 pg/ml, Z=-2.029, p=0.042). However, clinical assessment scales did not reveal any significant correlations with BDNF levels.
Conclusions:
These results suggest that BDNF may play a role in the pathophysiology of somatization disorder. Abstract Neuropathic pain is a major public health problem for which only few treatments are available. Translational studies showed that melatonin, a neurohormone acting on MT1 and MT2 receptors, has analgesic properties, likely through MT2 receptor. Here, we elucidated the effects of the novel selective melatonin MT2 receptor partial agonist N-{2-[(3-bromophenyl)-4-fluorophenylamino]ethyl}acetamide (UCM924) on neuropathic pain animal models and its mechanism of action.
In rat spinal L5-L6 nerve ligation (Kim and Chung's method) and spared nerve injury models (SNI), UCM924 (20-40 mg/kg, s.c.) produce a prolonged antiallodynic effect that is 1) dosedependent and blocked by the selective MT2 receptor antagonist 4P-PDOT, 2) superior to high doses of melatonin (150 mg/ kg) and comparable to gabapentin (100 mg/kg), but 3) without noticeable motor-sedative effects in the rotarod test. Using double staining immunohistochemistry, we found that MT2 receptors are expressed by glutamatergic neurons in the rostral ventrolateral periaqueductal gray (vlPAG). Using in-vivo electrophysiology combined to tail flick, we observed that microinjection of UCM924 into the vlPAG decreases tail flick responses, depressing the firing activity of ON cells and activating the firing of OFF cells, an effect MT2 receptor-dependent. Moreover, UCM 924 showed also antinoceptive properties in the hot plate model and in the formalin test. Altogether, these data demonstrate, for the first time, that selective MT2 receptor partial agonists have analgesic properties through modulation of brainstem descending antinociceptive pathways and indicate that MT2 receptors may be a novel target in the treatment of neuropathic pain.
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